The Zhitong Finance App learned that Conoa-B (02162) fell by more than 3%. As of press release, it was down 3.24% to HK$67.1, with a turnover of HK$253 million.

According to the news, Lyon's latest research report indicates that Conoa-B closed down 14.4% yesterday, after the company's overseas partner AstraZeneca (AZN.US) released positive data for Sone-VE in ESMO 2026. The bank attributed the sale to weak market sentiment after yesterday's major clinical catalyst.

The bank pointed out that AstraZeneca's complete analysis of sone-ve (CLDN18.2 ADC) Clarity Assessment 01 yesterday at ESMO 2026 was encouraging and in line with market expectations; however, one potential concern in the data was that the HR ratio of people intending to be treated with second-line treatment (2L ITT) was not as ideal. In addition, AstraZeneca's overnight management meeting was also positive. Management reiterated that the asset had a peak sales opportunity of $3 billion to $5 billion for second-tier and third-tier CLDN 18.2 positive gastric cancer indications.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.